12:00 AM
 | 
Oct 01, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

subcutaneous Velcade bortezomib regulatory update

The European Commission approved subcutaneous Velcade bortezomib from Johnson & Johnson to treat multiple myeloma (MM). An IV formulation of the small...

Read the full 89 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >